**BRIEF COMMUNICATION**

**Bordetella pertussis, Chlamydia pneumoniae, and Mycoplasma pneumoniae** Findings in Children During COVID-19 Pandemic in Finland

Ilari Kuitunen

Accepted: 8 July 2022 / Published online: 14 July 2022
© The Author(s) 2022

**Abstract**

Social restrictions effectively interrupted the typical respiratory virus circulation. The aim of this report is to describe how atypical pneumonia bacteria detections have changed during the COVID-19 pandemic in Finnish children. *Bordetella pertussis, Chlamydia pneumoniae*, and *Mycoplasma pneumoniae* findings were gathered from the National Infectious Diseases Register from 2015 to 2021 and stratified into three age groups (0–4, 5–9, and 10–14 years). Incidences per 100,000 children were calculated and 2020 and 2021 was compared to the mean incidence of reference years (2015–2019) by incidence rate ratios. *B. pertussis* incidence was 32% lower in 2020 and 88% lower in 2021 compared to reference years. *C. pneumoniae* detections decreased rapidly in 2020 and not a single detection of *C. pneumoniae* was reported to the register in 2021. *M. pneumoniae* incidence was 72% lower in 2020 and 89% lower in 2021 than in the reference years. All these findings were seen in all age groups. As the incidences of *B. pertussis, C. pneumoniae,* and *M. pneumoniae* detections have been low throughout the pandemic, it seems that the social restrictions have been effective in preventing the spreading of these respiratory bacteria in children.

**Keywords** Epidemiology · Surveillance · Bordetella pertussis · Chlamydia pneumoniae · Mycoplasma pneumoniae

**Introduction**

Social restriction set against COVID-19 in March 2020 interrupted the circulation of respiratory pathogens in Finland [1, 2]. Schools and day care facilities were then opened in May 2020 and have remained since open in Finland. Social restrictions set towards adults prevented Influenza and respiratory syncytial virus seasons in Finland in Winter 2020–2021 but did not prevent the spreading of rhinoviruses, which continued normally [3–5]. After the last restrictions were cleared mostly in August 2021, Finland had record high parainfluenza epidemic [6]. Majority of the published literature has focused on the epidemiology and incidences of viral respiratory infections during the COVID-19 pandemic.

A previous study from England reported a 98% reduction in *Bordetella pertussis* detections among infants (age less than 1 years) [7]. A study from Israeli found that the rates of *B. pertussis* and *Mycoplasma pneumoniae* decreased in hospitalized patients with respiratory tract infections during the early months of the pandemic. [8] Two Chinese studies reported major decreases in the *Mycoplasma pneumoniae* detections rates in Children during the pandemic [9, 10]. A large global study found also that the incidence of *M. pneumoniae* detections decreased especially with direct tests (polymerase chain reaction PCR), whereas the antibody detections did not decrease [11]. *Chlamydia pneumoniae* incidence has not been assessed in children during the pandemic.

The aim of this manuscript is to report the incidence of laboratory confirmed cases of *B. pertussis, C. pneumoniae,* and *M. pneumoniae* in Finnish children during the COVID-19 pandemic.
Methods

All laboratory confirmed findings of *B. pertussis*, *C. pneumoniae*, and *M. pneumoniae* were included from the National Infectious Disease Register of Finland. All diagnostic laboratories are mandated by the Law of Contagious Diseases to report all positive findings of notifiable diseases. Therefore, the coverage of the register is excellent [12]. As the register does not contain information on the number of tests performed, the estimation on the COVID-19 pandemic to the testing numbers was estimated based on the single regional laboratory data. Southern Savonia healthcare region and laboratory produces testing for a population of 100,000 (of those children approximately 13,000). For this study information on antibody tests performed from 2015 to 2021 were included.

*B. pertussis*, *C. pneumoniae*, and *M. pneumoniae* are tested in Finland as direct way as those part of the multiplex PCR panels. These samples are nasopharyngeal swabs and taken typically in acute respiratory infections and this test is typically used only in hospitalized patients in pediatric wards. The register also contains information on indirect findings (typically IgM positive serology and/or clear increase in IgG serology during two to four weeks). In cases of for example prolonged cough are these three pathogens actively searched in every patient with antibody tests. Prolonged cough is defined as cough lasting at least 6 to 8 weeks in Finland and then the examination of these three pathogens is part of the standard protocol.

Children aged 0–14 years were included and stratified into three age groups (0–4, 5–9, and 10–14 years) based on default stratification in the register. Study period was from January 2015 to December 2021. Mean yearly incidence per 100,000 children was calculated for the reference years (2015–2019) and compared to 2020 and 2021 by incidence rate ratios (IRR) with 95% confidence intervals (CI). The number of children in each age group was gathered from Population Information Statistics [13]. This study did not need ethical committee evaluation due to the register-based retrospective study design. This study has the research permission from the Southern Savonia healthcare officials to gain access to laboratory testing data.

Results

A total of 1050 *B. pertussis*, 397 *C. pneumoniae*, and 4922 *M. pneumoniae* detections were included from the register. The monthly incidence of *B. pertussis* decreased rapidly in the March 2020 and have remained low since to the end of 2021 (Figure 1). Incidence was 32% lower in 2020 and 88% lower in 2021 compared to reference years (Table 1). The most prominent decrease was observed among children aged 10–14 years in 2021 (IRR 0.03 CI 0.01–0.11).

*C. pneumoniae* incidence has been previously relatively low, but before the pandemic clear epidemic peak occurred in winter 2018–2019 (Figure 1). Detections decreased rapidly in 2020 and not a single detection of *C. pneumoniae* was reported to the register in 2021 (Table 1).

The monthly incidence of *M. pneumoniae* has had relatively predictable trends prior to pandemic (Figure 1). During the pandemic the monthly incidence has remained notably lower than in the reference years. The yearly
|                     | 2015–2019 |          | 2020 |          | 2021 |          |
|---------------------|-----------|----------|------|----------|------|----------|
|                     | N         | Incidence| N    | Incidence| N    | Incidence|
| **Bordetella pertussis** |           |          |      |          |      |          |
| Total               | 909       | 20.4     | 120  | 13.8     | 21   | 2.4      |
| 0–4 years           | 286       | 13.3     | 32   | 9.5      | 16   | 6.5      |
| 0–9 years           | 234       | 28.2     | 29   | 19.1     | 2    | 0.7      |
| 10–14 years         | 482       | 20.4     | 59   | 13.8     | 3    | 1.0      |
| **Chlamydia pneumoniae** |          |          |      |          |      |          |
| Total               | 397       | 8.5      | 19   | 2.2      | 0    | 0.0      |
| 0–4 years           | 26        | 1.8      | 1    | 0.4      | 0    | 0.0      |
| 0–9 years           | 131       | 8.4      | 3    | 1.0      | 0    | 0.0      |
| 10–14 years         | 240       | 15.1     | 15   | 4.9      | 0    | 0.0      |
| **Mycoplasma pneumoniae** |          |          |      |          |      |          |
| Total               | 4 574     | 102.6    | 249  | 28.6     | 99   | 11.5     |
| 0–4 years           | 512       | 35.8     | 36   | 14.1     | 12   | 2.9      |
| 0–9 years           | 1 702     | 111.3    | 94   | 30.7     | 32   | 10.6     |
| 10–14 years         | 2 360     | 158.2    | 119  | 38.5     | 55   | 17.6     |

**Table 1** Yearly number of detections and incidence in 2020 and 2021 compared to mean yearly incidence of reference years (2015–2019) by incidence rate ratios (IRR) with 95% confidence intervals.
incidence was 72% lower in 2020 and 89% lower in 2021 than in the reference years (Table 1).

Yearly number of tests decreased for M. pneumoniae and B. pertussis (Table 2). The decrease was more prominent in the first pandemic year than in the second. The number of C. pneumoniae antibody tests increased by 47.2% in 2020 and 80.4% in 2021 compared to the mean of five pre-pandemic years.

Discussion

The incidences of B. pertussis, C. pneumoniae, and M. pneumoniae have been notably lower during the COVID-19 pandemic in all aged children. Social restrictions and improved hand hygiene measures have most likely decreased the incidences of these respiratory bacteria. The decrease began right after the lockdown began in March 2020. Although the restrictions set towards children were partially eased already in May 2020 and children have attended to schools and day cares normally without masks since August 2020, the respiratory bacterial pathogen findings have remained in low levels.

The observed decrease in B. pertussis was 88% in our study, whereas the English study presented a decrease of 97%, but the detection rates in this study were relatively rare (only 21 detections in 2021), so these findings were practically similar [7]. The results of this study are also similar to the previous reports regarding the decrease in the detections of M. pneumoniae [8–11]. There were no previous studies focusing on C. pneumoniae. But the detection rate in Finnish children has been practically zero throughout the pandemic. Some reports have assessed possible co-infections in COVID-19 patients and C. pneumoniae has been found in adult-aged COVID-19 patients [14]. A Brazilian study tested COVID-19 patients with suspected COVID-19 by multiplex panels and found cases of C. pneumoniae in non-COVID-19 patients [15].

The main limitation of this study is the lack of testing numbers, as these are not reported to the National Infectious Disease Register. To overcome this issue, a subsample of one regional laboratory was analyzed which showed that although the testing rates were lower than previously, the testing continued. However, the reduced testing numbers could have been due to reduced disease burden instead of limited testing capacity. Thus, must be noted that the primary care visit rate returned to normal in Finland in August 2020 after being lower during the initial lockdown from March 2020 to June 2020, and the visit rate has remained normal since [16, 17]. The reason for the increased C. pneumoniae testing remains unknown and is interesting as the nationwide detections rate have been zero during the second pandemic year. Further limitation is that the register does not provide information on re-infections or co-infections as it records only the microbial findings per microbe. The main strength is the nationwide coverage and accuracy of the register.

Conclusion

In conclusion, the incidences of laboratory detected cases of B. pertussis, C. pneumoniae, and M. pneumoniae have been low throughout the pandemic period. Thus, it seems that the social restrictions have been effective in preventing the spreading of respiratory bacteria. How the ending of restrictions will affect to the detection rates should be addressed in the future.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s42399-022-01251-9.

Author Contribution IK as the only author did all the work.

Funding Open access funding provided by University of Eastern Finland (UEF) including Kuopio University Hospital.

Data Availability All data included as supplement.

Code Availability Not applicable.

Declarations

Ethics Approval According to Finnish research laws ethical approval was not needed due to the register-based retrospective study design. This study has research permission from Southern Savonia healthcare officials.

Consent to Participate Not applicable.

Consent for Publication Not applicable.

Competing Interests The author declares no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long

### Table 2 Yearly number of Bordetella pertussis, Chlamydia pneumoniae, and Mycoplasma pneumoniae antibody tests in Southern Savonia healthcare region. Pandemic years (2020 and 2021) compared to mean of five pre-pandemic years (2015 to 2019)

|                  | 2015–2019 | 2020 | 2021 |
|------------------|-----------|------|------|
|                  | N         | N    | Change | N    | Change |
| Bordetella pertussis | 138      | 44   | −62.1%  | 61   | −55.8% |
| Chlamydia pneumoniae | 89       | 43   | −51.7%  | 60   | −32.6% |
| Mycoplasma pneumoniae | 36      | 53   | +47.2%  | 65   | +80.6% |
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kuitunen I, Artama M, Mäkelä L, Backman K, Heiskanen-Kosma T, Renko M. Effect of social distancing due to the COVID-19 pandemic on the incidence of viral respiratory tract infections in children in Finland during early 2020. Pediatr Infect Dis J. 2020;39(12):e423–7. https://doi.org/10.1097/INF.0000000000002845.

2. Haapanen M, Renko M, Artama M, et al. The impact of the lockdown and the re-opening of schools and day cares on the epidemiology of SARS-CoV-2 and other respiratory infections in children - a nationwide register study in Finland. EClinicalMedicine. 2021;34:100807. https://doi.org/10.1016/j.eclinm.2021.100807.

3. Kuitunen I, Renko M. Lessons to learn from the current pandemic for future non-pharmaceutical interventions against the respiratory syncytial virus - nationwide register-study in Finland. Infect Dis (Lond). 2021;53(6):476–8. https://doi.org/10.1080/23744235.2021.1894351.

4. Kuitunen I. Influenza season 2020–2021 did not begin in Finland despite the looser social restrictions during the second wave of COVID-19: a nationwide register study. J Med Virol. 2021;93(9):5626–9. https://doi.org/10.1002/jmv.27048.

5. Kuitunen I, Artama M, Haapanen M, Renko M. Rhinovirus spread in children during the COVID-19 pandemic despite social restrictions-a nationwide register study in Finland. J Med Virol. 2021;93(10):6063–7. https://doi.org/10.1002/jmv.27180.

6. Kuitunen I, Artama M, Haapanen M, Renko M. Record high parainfluenza season in children after relaxation of COVID-19 restrictions in fall 2021-a nationwide register study in Finland. Influenza Other Respir Viruses. 2022. https://doi.org/10.1111/irv.12983.

7. Tessier E, Campbell H, Ribeiro S, et al. Impact of the COVID-19 pandemic on Bordetella pertussis infections in England. BMC Public Health. 2022;22(1):405. https://doi.org/10.1186/s12889-022-12830-9.

8. Oster Y, Michael-Gayego A, Rivkin M, Levinson L, Wolf DG, Nir-Paz R. Decreased prevalence rate of respiratory pathogens in hospitalized patients during the COVID-19 pandemic: possible role for public health containment measures? Clin Microbiol Infect. 2020;27(5):811–2. https://doi.org/10.1016/j.cmi.2020.12.007.

9. Chen J, Zhang J, Lu Z, et al. Mycoplasma pneumoniae among Chinese outpatient children with mild respiratory tract infections during the coronavirus disease 2019 pandemic. Microbiol Spectr. 2022;10(1):e0155021. https://doi.org/10.1128/spectrum.01550-21.

10. Zhang Y, Huang Y, Ai T, et al. Effect of COVID-19 on childhood Mycoplasma pneumoniae infection in Chengdu, China. BMC Pediatr. 2021;21(1):202. https://doi.org/10.1186/s12887-021-02679-z.

11. Meyer Sauteur PM, Beeton ML, et al. Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021. Euro Surveill. 2022;27(19):2100746. https://doi.org/10.2807/1560-7917.ES.2022.27.19.2100746.

12. Infectious Disease Register [Internet]; 2022 [updated Mar 10; cited Mar 12 2022]. Available from: https://hl.fi/en/web/infectious-diseases/surveillence/infectious-disease-register.

13. Population Information System, Statistics Finland [Internet]; 2022 [updated Mar 10; cited Mar 12 2022]. Available from: https://pxnet2.stat.fi/PXWeb/pxweb/hi/StatFin/StatFin__vrn_vaerak/.

14. De Francesco MA, Poiesi C, et al. Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features. J Infect. 2021;82(4):e4–7. https://doi.org/10.1016/j.jinf.2021.01.009.

15. Boschiiero MN, Duarte A, Palamim CVC, Alvarez AE, Mauch RM, Marson FAL. Frequency of respiratory pathogens other than SARS-CoV-2 detected during COVID-19 testing. Diagn Microbiol Infect Dis. 2022;102(2):115576. https://doi.org/10.1016/j.diagmicrobio.2021.115576.

16. Haapanen M, Renko M, Artama M, Kuitunen I. Systemic antibiotics and asthma medicines dispensed to 0–12 year olds significantly decreased during the COVID-19 pandemic in 2020. Acta Paediatr. 2022;111(2):376–82. https://doi.org/10.1111/apa.16144.

17. Kuitunen I, Haapanen M, Artama M, Renko M. Closing Finnish schools and day care centres had a greater impact on primary care than secondary care emergency department visits. Acta Paediatr. 2021;110(3):937–8.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.